Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

This publication has 15 references indexed in Scilit:

• Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction
  Journal of the American College of Cardiology, 2003
• Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension
  Cardiovascular Research, 2003
• Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
  Neurology, 2003
• The US Food and Drug Administration's Registry of Patients With Pergolide-Associated Valvular Heart Disease
  Mayo Clinic Proceedings, 2003
• 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) Induces Fenfluramine-Like Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro
  Molecular Pharmacology, 2003
• Drug-Related Valvular Heart Disease: Here We Go Again: Will We Do Better This Time?
  Mayo Clinic Proceedings, 2002
• Valvular Heart Disease in Patients Taking Pergolide
  Mayo Clinic Proceedings, 2002
• Pleuropulmonary Disease Due to Pergolide Use for Restless Legs Syndrome
  Chest, 2001
• Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
  New England Journal of Medicine, 1996
• Retroperitoneal Fibrosis in a Patient with Parkinsonʼs Disease Treated with Pergolide
  Clinical Neuropharmacology, 1995